{"podcast":{"title":"Neurology Minute","slug":"neurology-minute-15117","podcast_index_feed_id":15117,"rss_url":"https://neurologyminute.libsyn.com/rss","website_url":"https://www.aan.com/education-and-research/online-learning-programs/podcasts/neurology-minute-podcast","image_url":"https://static.libsyn.com/p/assets/3/0/c/3/30c3c82925660375e55e3c100dce7605/NM_PodcastIcon_1400x1400.png","author":"Anna Rehbein","episode_count":1956,"summary":"The Neurology Minute podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, Ph.D., FAAN, with contributions by experts from the Neurology journals, Neurology Today, Continuum, and more.","last_synced_at":"2026-06-25T18:20:17.428469+00:00","page_url":"https://stenobird.com/podcast/neurology-minute-15117"},"episode":{"title":"Maintenance Immunotherapy in MOGAD: Early Steroid Benefit, Dose Thresholds, and Disability Risk - Part 3","slug":"maintenance-immunotherapy-in-mogad-early-steroid-benefit-dose-thresholds-and-disability-risk-part-3","published_at":"2026-05-06T08:30:00+00:00","page_url":"https://stenobird.com/podcast/neurology-minute-15117/maintenance-immunotherapy-in-mogad-early-steroid-benefit-dose-thresholds-and-disability-risk-part-3","show_page_url":"https://stenobird.com/podcast/neurology-minute-15117","url":"https://neurologyminute.libsyn.com/maintenance-immunotherapy-in-mogad-early-steroid-benefit-dose-thresholds-and-disability-risk-part-3","audio_url":"https://traffic.libsyn.com/secure/neurologyminute/03_May_6th_2026_nm_v1.mp3?dest-id=1085030","summary":"In the last episode of this series, Dr. Justin Abbatemarco and Dr. Benjamin P. Trewin discuss how to apply this data into clinical practice. Read more about this abstract on the AAN website . Show transcript: Dr. Justin Abbatemarco: Hello, and welcome back. This is Justin Abbatemarco and I'm joined by Benjamin Trewin where we're reviewing top abstracts from the AAN annual meeting in Chicago. Today we're talking about his abstract maintenance immunotherapy and MOGAD, early steroid benefit, dose thresholds, and disability risk. Ben, we've done this really great job of dissecting the data, steroids, non-steroidal agents. How do you think about the treating MOGAD cases in clinic though? How do you try to put this data and the data we've talked about into clinical practice? Dr. Benjamin P. Trewin: It's obviously a very good and actionable question, and our research has always tried to focus on these dilemmas facing the clinician at the bedside. And so the way that we think about this is, of course, we try to come up with some rules or some guidelines to treat all patients, as that's the most effective way of giving the message, but we need to acknowledge there is variation within MOGAD patients. There are people with low relapsing propensity who will take a very long time to relapse. You'll need to follow them for a long time. And there are ones with high relapsing propensity. So some of our previous work, we actually reviewed thousands of MOGAD patients in the literature and found that if you follow them for more than five years, over 70% actually relapse. It's just a matter of following them. So acknowledging this variation in the patients is important, but at the same time, the guideline we would probably endorse based on our research is that all patients with MOGAD afte…","meta_description":"In the last episode of this series, Dr. Justin Abbatemarco and Dr. Benjamin P. Trewin discuss how to apply this data into clinical practice. Read more abo…","key_points":[],"chapters":[],"topics":[],"duration_seconds":185,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/neurology-minute-15117/episodes/maintenance-immunotherapy-in-mogad-early-steroid-benefit-dose-thresholds-and-disability-risk-part-3/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/neurology-minute-15117/maintenance-immunotherapy-in-mogad-early-steroid-benefit-dose-thresholds-and-disability-risk-part-3.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}